03.19.25 -- 'Fractional Hiring' At Your CDMO. Okay With You?

The revised EU GMP Annex 1 mandates a comprehensive Contamination Control Strategy, continuous environmental monitoring, and species-level contaminant identification to ensure compliance.

Here, we conduct a comprehensive analysis of diverse PROTAC (Proteolysis Targeting Chimeras) structures, evaluating their calculated physicochemical properties to identify key trends.

Since life science professionals hail from diverse backgrounds, educations, and work experiences, different mentorship models serve their varied development needs and learning styles.

Learn about strategies that can help build an understanding of risk assessment, in addition to how a study’s protocol requirements, packaging specifications, and more must be identified and addressed.

Watch as experts walk through several technologies and case studies, focusing on liquid-phase peptide synthesis, crystallization, method development for impurity analysis, and more.

Explore how certain drivers are impacting traditional drug development strategies and relationships with outsourced drug development and manufacturing partners.

Review a case study describing the selection of the optimal solid form of an API designed for pulmonary administration through the pulmonary route.

Brush up on guidance on how to demonstrate that a foreign-sourced reference drug is acceptable to the Minister of Health as a Canadian reference product for an Abbreviated New Drug Submission and Abbreviated Extraordinary Use New Drug Submission.

The HANU, a new photo-flow reactor, provides better process control, less risk in hazardous chemistry, less solvent use, and is better for the environment.

This portfolio of comprehensive research and development services is equipped to handle all your product development needs and bring your projects from concept to production.

Consider how our cost-efficient, innovative model can help to support your NCE programs from discovery to commercialization.